Follow this preprint

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection

Ajit Nair, Prajak Barde, Kasi V Routhu, Swaroop Vakkalanka, RP7214-2101 Study Group
doi: https://doi.org/10.1101/2023.02.08.23285565
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
00 Comments

Article usage

Article usage: February 2023 to January 2025

Show by monthAbstractFull-text HTMLPDF
Total                  1,24165376
Tweeted by 3
Back to top
Posted February 08, 2023.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML
Data/Code
Email
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection
Ajit Nair, Prajak Barde, Kasi V Routhu, Swaroop Vakkalanka, RP7214-2101 Study Group
medRxiv 2023.02.08.23285565; doi: https://doi.org/10.1101/2023.02.08.23285565
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.